ID   ETK-1
AC   CVCL_1206
SY   ETK1
DR   CLO; CLO_0009831
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03151925
DR   cancercelllines; CVCL_1206
DR   Cell_Model_Passport; SIDM00276
DR   ChEMBL-Cells; CHEMBL3308831
DR   ChEMBL-Targets; CHEMBL2366116
DR   Cosmic; 906861
DR   Cosmic-CLP; 906861
DR   DepMap; ACH-002237
DR   EGA; EGAS00001000978
DR   GDSC; 906861
DR   GEO; GSM1669779
DR   IARC_TP53; 21329
DR   LINCS_LDP; LCL-1789
DR   PharmacoDB; ETK1_348_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1206
DR   RCB; RCB1289
DR   Wikidata; Q54832847
RX   CelloPub=CLPUB00275;
RX   PubMed=9252136;
RX   PubMed=10761710;
RX   PubMed=16643607;
RX   PubMed=20143388;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35640676;
RX   PubMed=35839778;
WW   https://cell.brc.riken.jp/en/rcb/rbessp-25_announce
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=3.1%; Native American=0%; East Asian, North=74.88%; East Asian, South=17.31%; South Asian=0%; European, North=0.67%; European, South=4.05% (PubMed=30894373).
CC   Caution: Was incorrectly reported to be a SSP-25 contaminated cell line by Riken and thus also by ICLAC but it was later found out that SSP-25 was in fact contaminated by ETK-1 and not the other way around.
CC   Discontinued: RCB; RCB1289; true.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 10,12
ST   D5S818: 10
ST   D7S820: 11
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 37
//
RX   CelloPub=CLPUB00275;
RA   Zach S., Birgin E., Ruckert F.;
RT   "Primary cholangiocellular carcinoma cell lines.";
RL   J. Stem Cell Res. Transplant. 2:1013-1013(2015).
//
RX   PubMed=9252136; DOI=10.1002/hep.510260206;
RA   Enjoji M., Nakashima M., Honda M., Sakai H., Nawata H.;
RT   "Hepatocytic phenotypes induced in sarcomatous cholangiocarcinoma
RT   cells treated with 5-azacytidine.";
RL   Hepatology 26:288-294(1997).
//
RX   PubMed=10761710; DOI=10.1111/j.1349-7006.2000.tb00935.x;
RA   Enjoji M., Nakashima M., Nakamuta M., Nawata H.;
RT   "Transforming growth factor-alpha induces the differentiation of
RT   sarcomatoid cholangiocarcinoma cells.";
RL   Jpn. J. Cancer Res. 91:223-230(2000).
//
RX   PubMed=16643607; DOI=10.1111/j.1749-0774.2005.00007.x;
RA   Yoshino K., Iimura E., Saijo K., Iwase S., Fukami K., Ohno T.,
RA   Obata Y., Nakamura Y.;
RT   "Essential role for gene profiling analysis in the authentication of
RT   human cell lines.";
RL   Hum. Cell 19:43-48(2006).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007;
RA   Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y.,
RA   Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S.,
RA   Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.;
RT   "Development and characterization of human primary cholangiocarcinoma
RT   cell lines.";
RL   Am. J. Pathol. 192:1200-1217(2022).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//